{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:42Z","timestamp":1787841342397,"version":"build-2784847793"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T00:00:00Z","timestamp":1494028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Non-Hodgkin\u2019s lymphoma (NHL) constitutes a collection of lymphoproliferative disorders with diverse biologic, histologic, and clinical features. With a better understanding of the molecular pathogenesis, recently there have been major advances in the treatment of NHLs including addition of novel monoclonal antibodies, targeted therapies, and immune activators to the therapy armamentarium. Despite these remarkable developments, autologous hematopoietic cell transplantation (auto-HCT) remains not only a standard-of-care curative option for aggressive NHL but also an important therapeutic option for indolent NHL. In NHL, for patients with high-risk features, including those heavily pretreated or with refractory disease or those experiencing failure after an auto-HCT, allogeneic HCT (allo-HCT) remains the only curative option. In this review, we briefly discuss the role of transplantation in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). In DLBCL patients, we discuss the role of HCT in clinically and biologically defined ultra-high-risk disease. In FL patients, auto-HCT is best reserved for relapsed chemosensitive patients after two to three lines of prior chemoimmunotherapies, who are not candidates for allo-HCT, either because of donor unavailability, associated comorbidities, or patient preference. Reduced-intensity conditioning allo-HCT offers the curative option for patients with relapsed\/refractory FL. Although the emergence of targeted, biologic, and immunological therapies is welcoming, it is currently unclear how these new therapies might enhance or replace allo-HCT. Until we have further definitive data, allo-HCT remains the only curative option.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,6,13]],"date-time":"2017-06-13T23:32:00Z","timestamp":1497396720000},"page":"277-284","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":29,"title":["Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma"],"prefix":"10.4103","volume":"10","author":[{"given":"Narendranath","family":"Epperla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.hemonc.2017.05.004_b0005","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.004_b0010","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0015","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0020","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.004_b0025","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0030","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.13276","article-title":"A clinician\u2019s guide to double hit lymphomas","volume":"168","author":"Cheah","year":"2015","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0035","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0040","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0045","doi-asserted-by":"crossref","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the international DLBCL rituximab-CHOP consortium program. Blood 2013; 121: 4021\u201331 [quiz 250].","DOI":"10.1182\/blood-2012-10-460063"},{"key":"10.1016\/j.hemonc.2017.05.004_b0050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0055","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0060","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2015.01.009","article-title":"MYC alterations in diffuse large B-cell lymphomas","volume":"52","author":"Karube","year":"2015","journal-title":"Semin Hematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0065","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0070","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0075","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Horn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0080","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0085","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.2016.68.2740","article-title":"Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation","volume":"35","author":"Herrera","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0090","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3324\/haematol.2009.007005","article-title":"Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study","volume":"94","author":"Vitolo","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.004_b0095","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.2003.01.117","article-title":"Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin\u2019s lymphoma: an Italian multicenter randomized trial","volume":"21","author":"Martelli","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0100","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa031770","article-title":"Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support","volume":"350","author":"Milpied","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.004_b0105","doi-asserted-by":"crossref","unstructured":"Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev; 2008. CD004024.","DOI":"10.1002\/14651858.CD004024.pub2"},{"key":"10.1016\/j.hemonc.2017.05.004_b0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ctrv.2007.02.002","article-title":"High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma\u2014results of a comprehensive meta-analysis","volume":"33","author":"Greb","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.hemonc.2017.05.004_b0115","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.004_b0120","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002\u20131)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0125","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2016.67.2980","article-title":"Randomized Trial comparing R-CHOP versus high-dose sequential chemotherapy in high-risk patients with diffuse large B-cell lymphomas","volume":"34","author":"Cortelazzo","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0130","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/cncr.28642","article-title":"Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival","volume":"120","author":"Cohen","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.05.004_b0135","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hemonc.2017.05.004_b0140","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0145","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.bbmt.2014.06.036","article-title":"Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation","volume":"20","author":"Hamadani","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2141.2008.07365.x","article-title":"Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience","volume":"143","author":"Rezvani","year":"2008","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0160","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1200\/JCO.2008.17.3328","article-title":"Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Thomson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0165","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbmt.2009.09.002","article-title":"Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"16","author":"Sirvent","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0170","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0175","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0180","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbmt.2013.01.024","article-title":"Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma","volume":"19","author":"Hamadani","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0185","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.bbmt.2015.05.007","article-title":"Impact of pretransplantation 18F-fluorodeoxy glucose-positron emission tomography status on outcomes after allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma","volume":"21","author":"Bachanova","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0195","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2004-03-0982","article-title":"Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Lenz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0200","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0205","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0210","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0215","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","article-title":"High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin\u2019s lymphoma: results from the randomized European CUP trial","volume":"21","author":"Schouten","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0220","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1200\/JCO.2007.15.5358","article-title":"Impact of rituximab and\/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study","volume":"26","author":"Sebban","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0225","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0230","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","article-title":"Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study","volume":"21","author":"Montoto","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hemonc.2017.05.004_b0235","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2003-04-1205","article-title":"Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma","volume":"102","author":"van Besien","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0240","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.bbmt.2015.07.028","article-title":"Reduced-intensity allografting as first transplantation approach in relapsed\/refractory grades one and two follicular lymphoma provides improved outcomes in long-term survivors","volume":"21","author":"Klyuchnikov","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0245","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/bmt.2015.223","article-title":"Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma","volume":"51","author":"Klyuchnikov","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0250","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1200\/JCO.2007.11.5477","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin\u2019s lymphoma","volume":"26","author":"Rezvani","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0255","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.bbmt.2007.11.004","article-title":"Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning","volume":"14","author":"Hari","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0260","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.3324\/haematol.2009.017608","article-title":"Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials","volume":"95","author":"Pinana","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.hemonc.2017.05.004_b0265","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0270","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/bmt.2013.83","article-title":"The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT","volume":"48","author":"Robinson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0275","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/bmt.2015.158","article-title":"Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed\/refractory follicular lymphoma","volume":"50","author":"Yano","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0280","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.28243","article-title":"Stem cell transplantation for follicular lymphoma relapsed\/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project","volume":"119","author":"Evens","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.hemonc.2017.05.004_b0285","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.bbmt.2011.01.016","article-title":"Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901","volume":"17","author":"Shea","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0290","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.bbmt.2016.04.014","article-title":"Reduced-intensity conditioning with fludarabine, cyclophosphamide, and high-dose rituximab for allogeneic hematopoietic cell transplantation for follicular lymphoma: a phase two multicenter trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"22","author":"Laport","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0295","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.bbmt.2010.11.004","article-title":"Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response","volume":"17","author":"Tomblyn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0300","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bbmt.2007.06.016","article-title":"Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index","volume":"14","author":"Vose","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0305","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0310","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0315","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0320","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hemonc.2017.05.004_b0325","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1038\/bmt.2015.184","article-title":"Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?","volume":"50","author":"Epperla","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0330","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.hemonc.2017.05.004_b0335","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00277-011-1395-9","article-title":"Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study","volume":"91","author":"Rigacci","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hemonc.2017.05.004_b0340","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1200\/JCO.2009.26.9100","article-title":"T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma","volume":"28","author":"Thomson","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387617300407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:27Z","timestamp":1787838627000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02275670-201710040-00020"}},"subtitle":["Current controversies and advances"],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2017.05.004","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}